J INTS BIO Shares Interim Preclinical Results of 'JIN-001' for Drug-Resistant Ovarian Cancer

SEOUL, South Korea, Oct. 23, 2024 — J INTS BIO, a prominent entity in oncology drug research, has unveiled preliminary preclinical findings regarding its innovative second-generation synthetic HSP90 inhibitor, JIN-001, at the ENA (EORTC-NCI-AACR) Symposium in Barcelona, Spain, from October 23-25, 2024. These findings highlight JIN-001's potential as a new treatment for cancer patients who have developed resistance to existing therapies, marking a crucial advancement in overcoming this significant hurdle.

Vice President of J INTS BIO, Ethan Seah, revealed these insights during a poster presentation at the symposium, focusing on the preclinical evaluation of the novel oral HSP90 inhibitor, JIN-001. Ovarian cancer, one of the most lethal gynecological malignancies, is often diagnosed at an advanced stage in approximately 70% of patients. Although many initially respond to traditional chemotherapy, resistance frequently develops, leading to disease progression and relapse. JIN-001 was created to tackle this problem by targeting heat shock protein 90 (HSP90), a molecular chaperone essential for cancer cells to adapt to therapeutic stress and survive.

Inhibiting HSP90 with JIN-001 interferes with the cancer cell's ability to evolve and develop resistance to chemotherapy, thus preserving the efficacy of conventional treatments. The preclinical studies presented at the symposium particularly examined the drug's effectiveness when combined with established chemotherapeutic agents, providing new optimism for patients with resistant cancer.

The preclinical study's objective was to assess JIN-001's effectiveness in ovarian cancer cell lines, including those resistant to widely used chemotherapies like paclitaxel and cisplatin. Researchers exposed both standard ovarian cancer cells and chemo-resistant strains to varying concentrations of JIN-001, either alone or in combination with paclitaxel (PTX) or cisplatin (Cis).

Key points from the study include:
- Cell Lines Tested: Ovarian cancer cell lines (OV90, TOV21G, OVCAR3) and chemo-resistant lines (OV90/PTX200, TOV21G/PTX100, OVCAR3-CisR) were used to assess the drug's effectiveness.
- Methods: The researchers gauged cell viability, comparing outcomes between monotherapy with JIN-001 and combination therapy with conventional chemotherapy agents.

The most impressive results were observed when JIN-001 was combined with traditional chemotherapy drugs. In the resistant OV90/PTX200 cell line, the IC50 value of paclitaxel dropped from 0.204 μM to 0.043 μM when combined with JIN-001, indicating a significant improvement in therapeutic efficacy. Similarly, in the cisplatin-resistant OVCAR3-CisR cell line, combining JIN-001 with cisplatin lowered the IC50 of cisplatin from 9.643 μM to 0.142 μM.

These interim results strongly imply that JIN-001 could be a groundbreaking companion therapy for patients with ovarian cancer. By inhibiting HSP90, JIN-001 boosts the efficacy of existing chemotherapies by limiting the adaptability and variability of cancer cells, thus preventing them from overcoming treatments. The J INTS BIO research team remarked, "The synergy between JIN-001 and standard chemotherapy agents is highly encouraging. It signifies a potential new treatment paradigm for cancer patients. We're dedicated to the ongoing clinical development of JIN-001 to ensure its efficacy and safety, hoping it will offer a transformative solution to combat chemotherapy resistance."

JIN-001 has demonstrated significant promise as an innovative therapeutic agent, especially for tackling chemotherapy resistance. J INTS BIO remains committed to expediting the clinical development of JIN-001, aiming to extend its application beyond ovarian cancer to other types, such as glioblastoma. Collaborative research with MD Anderson Cancer Center on JIN-001’s potential in glioblastoma has already shown positive preclinical outcomes, with a Phase 1 trial expected in 2025.
 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!